COVID-19 Vaccination Strategies Should Consider Infection Risk in CAR T-cell Therapy Recipients

Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.

Although CAR T-cell therapies have demonstrated unprecedented activity in patients with heavily pretreated relapsed/refractory hematologic malignancies, they are marked by a significant risk of infections and may limit the efficacy of COVID-19 vaccines.

Muhammad Bilal Abid, MD, discusses immune-compromising factors that are indigenous to CAR T-cell recipients, the immunogenic potential of different COVID-19 vaccines, determinants of response, and the potential need for booster strategies.